ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.027,59
-0,38%
S&P 500
5.308,15
1,17%
US Dollar vs BRL
5,1378
0,17%
Bitcoin
66.100,99
7,40%
Brent Oil
82,71
0,19%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Tenaya Therapeutics Inc (TNYA)

  7. Tenaya Therapeutics Inc (TNYA) Notícias

TNYA

Tenaya Therapeutics (TNYA)

Tenaya Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:TNYA
DataHoraFonteTítuloCódigoCompanhia
14/05/202417:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNYATenaya Therapeutics Inc
14/05/202417:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNYATenaya Therapeutics Inc
14/05/202417:05GlobeNewswire Inc.Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
02/05/202418:00GlobeNewswire Inc.Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual MeetingNASDAQ:TNYATenaya Therapeutics Inc
18/03/202417:05GlobeNewswire Inc.Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
18/03/202409:30GlobeNewswire Inc.Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications MedicineNASDAQ:TNYATenaya Therapeutics Inc
27/02/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNYATenaya Therapeutics Inc
27/02/202418:30GlobeNewswire Inc.Tenaya Therapeutics to Participate in Upcoming March Investor ConferencesNASDAQ:TNYATenaya Therapeutics Inc
26/02/202410:30GlobeNewswire Inc.Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature CommunicationsNASDAQ:TNYATenaya Therapeutics Inc
16/02/202422:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TNYATenaya Therapeutics Inc
08/02/202419:25Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TNYATenaya Therapeutics Inc
08/02/202410:00GlobeNewswire Inc.Tenaya Therapeutics Announces Pricing of Underwritten OfferingNASDAQ:TNYATenaya Therapeutics Inc
31/01/202418:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TNYATenaya Therapeutics Inc
03/01/202410:30GlobeNewswire Inc.Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:TNYATenaya Therapeutics Inc
21/11/202318:30GlobeNewswire Inc.Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:TNYATenaya Therapeutics Inc
08/11/202318:05GlobeNewswire Inc.Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
26/10/202309:30GlobeNewswire Inc.Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular CardiomyopathyNASDAQ:TNYATenaya Therapeutics Inc
09/10/202309:30GlobeNewswire Inc.Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific MeetingNASDAQ:TNYATenaya Therapeutics Inc
05/10/202309:30GlobeNewswire Inc.Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic CardiomyopathyNASDAQ:TNYATenaya Therapeutics Inc
02/10/202318:30GlobeNewswire Inc.Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac RegenerationNASDAQ:TNYATenaya Therapeutics Inc
21/09/202317:05GlobeNewswire Inc.Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical ConferencesNASDAQ:TNYATenaya Therapeutics Inc
31/08/202317:05GlobeNewswire Inc.Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare ConferenceNASDAQ:TNYATenaya Therapeutics Inc
09/08/202317:05GlobeNewswire Inc.Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
02/08/202317:05GlobeNewswire Inc.Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth ConferenceNASDAQ:TNYATenaya Therapeutics Inc
10/05/202317:36Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TNYATenaya Therapeutics Inc
10/05/202317:29Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TNYATenaya Therapeutics Inc
10/05/202317:19GlobeNewswire Inc.Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
03/05/202309:00GlobeNewswire Inc.Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual MeetingNASDAQ:TNYATenaya Therapeutics Inc
02/05/202309:43Dow Jones NewsTenaya Therapeutics Gets FDA Fast-Track Designation for TN-201NASDAQ:TNYATenaya Therapeutics Inc
02/05/202308:50GlobeNewswire Inc.Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201NASDAQ:TNYATenaya Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:TNYA

Seu Histórico Recente

BIT
UC6BFL
Unicredit Bank
LSE
0ROR
Spice Private Equity
DGFX
WELUPSUSDT
Welups Blockchain
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados